Clinical Trial

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.
Protocol Amendment History 5 changes
notable Trial sites expanded: 58 -> 62 locations 2026-07-09
notable Trial sites expanded: 53 -> 56 locations 2026-05-20
notable Trial sites expanded: 39 -> 53 locations 2026-04-23
notable Primary completion pushed: 2026-10-16 -> 2027-09-15 2026-04-23
minor Completion pushed: 2026-10-30 -> 2027-09-29 2026-04-23
Trial Details
NCT Number NCT07288138
Lead Sponsor Eccogene
Conditions Metabolic Dysfunction-associated Steatohepatitis
Enrollment 160 participants
Start Date 2025-12-15
Primary Completion 2027-09-15 (estimated)
Study Completion 2027-09-29 (estimated)
Updated on ClinicalTrials.gov 2026-08-06